Compare ADBT & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADBT | NSPR |
|---|---|---|
| Founded | 2017 | 2005 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.9M | 38.9M |
| IPO Year | 2025 | 2009 |
| Metric | ADBT | NSPR |
|---|---|---|
| Price | $0.08 | $0.54 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $2.67 |
| AVG Volume (30 Days) | ★ 3.8M | 408.2K |
| Earning Date | 11-20-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | N/A | ★ $2,310,000.00 |
| Revenue This Year | N/A | $9.38 |
| Revenue Next Year | N/A | $67.09 |
| P/E Ratio | $10.89 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.07 | $0.43 |
| 52 Week High | $4.99 | $2.17 |
| Indicator | ADBT | NSPR |
|---|---|---|
| Relative Strength Index (RSI) | 6.62 | 42.65 |
| Support Level | N/A | $0.44 |
| Resistance Level | $0.13 | $0.79 |
| Average True Range (ATR) | 0.01 | 0.13 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 19.53 | 19.41 |
Advasa Holdings Inc is a financial technology and services company that offers a suite of financial services and solutions. Its earned wage access (EWA) service, named 'FUKUPE', provides employees with real-time access to their earned wages through cashless receipts and settlements that integrate seamlessly with wallets, cards, and bank accounts. The company also licenses its EWA technology portfolio and offers OEM (original equipment manufacturer) services. The company generates the majority of revenue from the provision of software maintenance services. Geographically, the company operates only in Japan.
InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.